Framingham congestive-heart-failure score

From Citizendium
Revision as of 11:50, 17 August 2024 by Pat Palmer (talk | contribs) (resolved duplicate ref)
Jump to navigation Jump to search
This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

The Framingham congestive-heart-failure score can be used to diagnose heart failure and monitor its response to treatment.[1]

Calculation of the score

  • Major findings (1 point each)
  • Minor findings (0.5 point each)
    • Orthopnea
    • Reduction in exercise tolerance
    • Resting heart rate > 100 bpm
    • Hepatomegaly
    • Peripheral edema

Clinical uses of the score

The score can be used (two major or one major and two minor criteria) to diagnose heart failure.[1]

The score can also be used to monitor the response to treatment for heart failure. Targeting a clinical score to a score of 2 or less may[2] or may[3] not be similar to targeting brain natriuretic peptide (BNP) level.

References

  1. 1.0 1.1 Ho KK, Pinsky JL, Kannel WB, Levy D (1993). "The epidemiology of heart failure: the Framingham Study.". J Am Coll Cardiol 22 (4 Suppl A): 6A-13A. PMID 8376698.
  2. Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG et al. (2009). "N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial.". J Am Coll Cardiol 55 (1): 53-60. DOI:10.1016/j.jacc.2009.02.095. PMID 20117364. Research Blogging.
  3. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM (2000). "Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations.". Lancet 355 (9210): 1126-30. PMID 10791374.